Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2002 1
2003 3
2004 3
2005 1
2006 2
2007 1
2009 2
2010 1
2011 2
2014 1
2015 6
2016 3
2018 2
2019 1
2020 3
2021 4
2022 2
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Among authors: ter borg pcj. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group, the Dutch Initiative on Crohn, Colitis (ICC). van Linschoten RCA, et al. Among authors: ter borg pcj. Dig Dis Sci. 2024 Jun;69(6):2165-2174. doi: 10.1007/s10620-024-08410-z. Epub 2024 Apr 9. Dig Dis Sci. 2024. PMID: 38594435 Free PMC article. Clinical Trial.
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, Hoentjen F, van der Woude CJ; LADI study group. Jansen FM, et al. Among authors: ter borg pcj. J Crohns Colitis. 2023 Nov 24;17(11):1771-1780. doi: 10.1093/ecco-jcc/jjad101. J Crohns Colitis. 2023. PMID: 37310877 Free PMC article. Clinical Trial.
Efficacy of different bowel preparation regimen volumes for colorectal cancer screening and compliance with European Society of Gastrointestinal Endoscopy performance measures.
Theunissen F, Lantinga MA, Ter Borg PCJ, Ouwendijk RJT, Siersema PD, Bruno MJ; Trans. IT foundation study group. Theunissen F, et al. Among authors: ter borg pcj. United European Gastroenterol J. 2023 Jun;11(5):448-457. doi: 10.1002/ueg2.12386. Epub 2023 May 15. United European Gastroenterol J. 2023. PMID: 37190897 Free PMC article.
Sex Differences in Neoplastic Progression in Barrett's Esophagus: A Multicenter Prospective Cohort Study.
Roumans CAM, Zellenrath PA, Steyerberg EW, Lansdorp-Vogelaar I, Doukas M, Biermann K, Alderliesten J, van Ingen G, Nagengast WB, Karrenbeld A, Ter Borg F, Hage M, Ter Borg PCJ, den Bakker MA, Alkhalaf A, Moll FCP, Brouwer-Hol L, van Baarlen J, Quispel R, van Tilburg A, Burger JPW, van Tilburg AJP, Ooms AHAG, Tang TJ, Romberg-Camps MJL, Goudkade D, Bruno MJ, Rizopoulos D, Spaander MCW. Roumans CAM, et al. Among authors: ter borg pcj. Cancers (Basel). 2022 Jul 1;14(13):3240. doi: 10.3390/cancers14133240. Cancers (Basel). 2022. PMID: 35805012 Free PMC article.
Implementation of mandatory ERCP registration in The Netherlands and compliance with European Society of Gastrointestinal Endoscopy performance measures: a multicenter database study.
Theunissen F, van der Wiel SE, Ter Borg PCJ, Koch AD, Ouwendijk RJT, Slangen RME, Siersema PD, Bruno MJ; Trans.IT foundation study group. Theunissen F, et al. Among authors: ter borg pcj. Endoscopy. 2022 Mar;54(3):262-267. doi: 10.1055/a-1499-7477. Epub 2021 Jun 9. Endoscopy. 2022. PMID: 34107538 Free article.
Incidence and prevalence of primary biliary cholangitis in the Netherlands - A nationwide cohort study.
de Veer RC, van Hooff MCB, Werner E, Beuers U, Drenth JPH, Cuperus FJC, van Hoek B, Veldt BJ, Klemt-Kropp M, van Meer S, Verdonk RC, Flink HJ, Vrolijk JM, Gevers TJG, Ponsioen CY, Ter Borg MJ, Soufidi K, Boersma F, de Jonge HJM, Wolfhagen FHJ, Baak LC, Onderwater SL, van Bergeijk JD, van Putten PG, de Bruin GJ, Adang RPR, Aparicio-Pages MN, de Boer W, Borg FT, van Soest H, Janssen HLA, Hansen BE, Erler NS, van der Meer AJ; Dutch PBC Study Group. de Veer RC, et al. JHEP Rep. 2024 Jun 6;6(8):101132. doi: 10.1016/j.jhepr.2024.101132. eCollection 2024 Aug. JHEP Rep. 2024. PMID: 39113899 Free PMC article.
40 results